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Introduction {#cncr32465-sec-0005}
============

The effectiveness and outcomes of cancer treatments are historically based on the evaluation of clinician‐reported outcomes and measures such as morbidity and survival. Over the last few decades, patient‐reported health‐related quality of life (HRQOL) measures have been recognized as some of the most important tools for evaluating treatments.[1](#cncr32465-bib-0001){ref-type="ref"} Another aspect of the patient perspective that is gaining attention, and might even be the ultimate patient‐reported outcome, is patient satisfaction with the treatment\'s outcomes. Yet, patient satisfaction is not evaluated in the majority of HRQOL measures, and existing satisfaction measures focus on satisfaction with overall care rather than satisfaction with treatment outcomes.[2](#cncr32465-bib-0002){ref-type="ref"}, [3](#cncr32465-bib-0003){ref-type="ref"}

The patient perspective is especially relevant in the treatment of patients with spinal metastases because of the palliative intent of the procedures. Although radiation and/or surgery have been shown to effectively relieve symptoms and improve HRQOL for patients with spinal metastases,[4](#cncr32465-bib-0004){ref-type="ref"}, [5](#cncr32465-bib-0005){ref-type="ref"}, [6](#cncr32465-bib-0006){ref-type="ref"} the level of satisfaction with these treatment outcomes is largely unknown.[7](#cncr32465-bib-0007){ref-type="ref"}, [8](#cncr32465-bib-0008){ref-type="ref"} Understanding patient factors that affect treatment satisfaction is important for enhancing patient decision making and for determining further areas of importance to optimize treatment outcomes. Other disciplines have studied patient satisfaction, but to the best of our knowledge, this is the first study to prospectively investigate the degree of patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases and, furthermore, to evaluate how HRQOL is related to patient satisfaction.

Materials and Methods {#cncr32465-sec-0006}
=====================

Study Design {#cncr32465-sec-0007}
------------

This study was part of an international, multicenter, observational cohort study conducted by the AOSpine Knowledge Forum Tumor, which included patients between the ages of 18 and 75 years who were treated with surgery with or without radiotherapy or with radiotherapy alone for spinal metastases (Epidemiology, Process and Outcomes of Spine Oncology \[EPOSO\]; ClinicalTrials.gov identifier NCT01825161). Patients were not eligible for inclusion if they were diagnosed with a primary spinal bone tumor or central nervous system tumor. The protocol was approved by the ethics board of each of the participating sites, and all patients provided written informed consent.

Demographic, diagnostic, treatment, adverse event, and HRQOL data were prospectively collected. HRQOL was evaluated with the Numeric Rating Scale pain score, the 3‐level version of the EuroQol 5‐Dimension (EQ‐5D‐3L) instrument, and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ2.0)[9](#cncr32465-bib-0009){ref-type="ref"} at the baseline and 6, 12, and 26 weeks after treatment.

Patient Satisfaction {#cncr32465-sec-0008}
--------------------

The core set of SOSGOQ2.0 questions evaluates 5 domains, including physical function, pain, neurological function, mental health, and social function. After treatment, the SOSGOQ2.0 is extended by 7 questions reflecting the different domains and evaluating patient satisfaction.

Patient satisfaction was derived from item 21 of the SOSGOQ2.0. It evaluates on a 5‐point response scale the following: "Are you satisfied with the results of your spine tumor management?" The response categories were condensed to patients who were somewhat satisfied or very satisfied being classified as satisfied and patients who were very dissatisfied or somewhat dissatisfied being classified as dissatisfied to ensure adequate numbers in the different categories. Patients who were neither satisfied nor dissatisfied were regarded as neutral.

For this study, patients were included in the analysis if they received treatment between August 2013 and February 2018, had data available regarding satisfaction, and had at least 6 months of follow‐up or died before that time point.

Statistical Analysis {#cncr32465-sec-0009}
--------------------

Standard descriptive statistics were used to represent demographic data (means and SDs or medians and ranges for continuous variables and absolute numbers and frequency distributions for categorical variables). The Student *t* test, the chi‐square test, and the Fisher exact test were used to compare differences in means and proportions between patients who underwent surgery with or without radiotherapy and patients who underwent radiotherapy alone. The Cochran‐Armitage test for trend was applied to examine linear trends in ordinal data. The primary endpoint of satisfaction was evaluated 12 weeks after treatment, with the information at 6 weeks after treatment carried forward in case of missing values at 12 weeks to minimize the loss of data (last observation carried forward \[LOCF\]). A sensitivity analysis was performed with a per‐protocol analysis, which excluded patients with missing information at the primary endpoint of 12 weeks. Mixed effect models were used to test for differences in HRQOL between satisfied and dissatisfied patients within the surgery or radiotherapy group. Patients classified as neutral were included in the group of dissatisfied patients for the mixed effect models. All statistical analyses were performed with SAS (version 9.4; SAS Institute, Inc, Cary, North Carolina). Significance was defined as *P* \< .05.

Results {#cncr32465-sec-0010}
=======

With the LOCF approach, satisfaction data were available for 351 patients at 12 weeks, including 219 patients treated with surgery with or without radiotherapy and 132 patients treated with radiotherapy alone. For 88 of these 351 patients, the satisfaction information was carried forward from the 6‐week visit.

The mean age at the time of treatment was 59.2 years (SD, 10.3 years); 54.7% were female; and the most common primary tumors were breast cancer (27%), lung cancer (17%), and renal cell cancer (16%). Of the patients who underwent surgery with or without radiotherapy, 104 were treated with surgery alone, and 115 received adjuvant radiotherapy. Adjuvant conventional external‐beam radiotherapy (EBRT) was given to 48 patients (41.7%); 53 (46.1%) received postoperative stereotactic body radiotherapy (SBRT); and for 14 patients (12.2%), the radiation modality was unknown. Of the 132 patients treated with radiotherapy alone, 51 (39%) were treated with conventional EBRT, and 81 (61%) were treated with SBRT.

The median number of operated vertebral levels was 5, and the mean operating time was 243 minutes (SD, 119 minutes). A posterior surgical approach was performed in 82% of the patients (n = 180), an anterior approach was performed in 4% (n = 9), and a combined anterior‐posterior approach was performed in 3% (n = 7). A palliative procedure with stabilization and limited decompression was performed in 45 patients (21%), intralesional curettage (subtotal or gross total) was performed in 82 patients (37%), and an en bloc procedure was performed in 18 patients (8%). Cement augmentation was used in the minority of patients with vertebroplasty in 19, kyphoplasty in 6, and another type of cement augmentation in 4.

Of the patients treated with radiotherapy alone, 81 (62%) underwent SBRT, and 51 (39%) underwent conventional EBRT, with a median number of treated levels of 1 (interquartile range, 1‐3). The median total dose in the conventional EBRT group was 20 Gy in 5 fractions, and the median total dose in the SBRT group was 24 Gy in 2 fractions. The baseline characteristics of both treatment groups are summarized in Table [1](#cncr32465-tbl-0001){ref-type="table"}.

###### 

Baseline Characteristics per Treatment Group of the Analysis Population

  Characteristic                                  Surgery With or Without Radiotherapy (n = 219)   Radiotherapy Alone (n = 131)                                                                                  
  ----------------------------------------------- ------------------------------------------------ ------------------------------ --------------------------------------------------- ------------ ------------- ---------------------------------------------------
  Age at surgery/radiotherapy                     183                                              36                             .208[a](#cncr32465-note-0003){ref-type="fn"}        101          31            .597[a](#cncr32465-note-0003){ref-type="fn"}
  Mean (SD), y                                    58.2 (10.2)                                      59.7 (12.4)                                                                        60.3 (9.1)   60.5 (11.5)    
  Sex, No. (%)                                    183                                               36                            .932[b](#cncr32465-note-0004){ref-type="fn"}        101          31            .160[b](#cncr32465-note-0004){ref-type="fn"}
  Female                                          98 (53.6)                                        19 (52.8)                                                                          54 (53.5)    21 (67.7)      
  Male                                            85 (46.4)                                        17 (47.2)                                                                          47 (46.5)    10 (32.3)      
  ECOG classification, No. (%)                    181                                              36                             .056[c](#cncr32465-note-0005){ref-type="fn"}        100          30            .388[c](#cncr32465-note-0005){ref-type="fn"}
  0                                               20 (11.0)                                        2 (5.6)                                                                            43 (43.0)    9 (30.0)       
  1                                               79 (43.6)                                        9 (25.0)                                                                           49 (49.0)    18 (60.0)      
  2                                               39 (21.5)                                        15 (41.7)                                                                          3 (3.0)      2 (6.7)        
  3                                               31 (17.1)                                        6 (16.7)                                                                           5 (5.0)      1 (3.3)        
  4                                               12 (6.6)                                         4 (11.1)                                                                           0 (0.0)      0 (0.0)        
  Site of the primary cancer, No. (%)             183                                              36                             .268[b](#cncr32465-note-0004){ref-type="fn"}        101          31            .941[d](#cncr32465-note-0006){ref-type="fn"}
  Breast                                          39 (21.3)                                        7 (19.4)                                                                           37 (36.6)    12 (38.7)      
  Lung                                            32 (17.5)                                        10 (27.8)                                                                          13 (12.9)    3 (9.7)        
  Prostate                                        13 (7.1)                                         4 (11.1)                                                                           15 (14.9)    6 (19.4)       
  Kidney                                          36 (19.7)                                        2 (5.6)                                                                            14 (13.9)    5 (16.1)       
  Other                                           63 (34.5)                                        13 (36.1)                                                                          22 (21.8)    5 (16.1)       
  Presence of other metastases                    139                                              29                             .694[b](#cncr32465-note-0004){ref-type="fn"}        101          31            .856[b](#cncr32465-note-0004){ref-type="fn"}
  None                                            72 (52)                                          14 (48)                                                                            19 (18.8)    4 (12.9)       
  Brain                                           10 (7.2)                                         3 (10.3)                                                                           11 (10.9)    3 (9.7)        
  Visceral                                        57 (41)                                          12 (41.4)                                                                          36 (35.6)    13 (41.9)      
  ASIA Impairment Scale, No. (%)                  183                                              36                             .223[c](#cncr32465-note-0005){ref-type="fn"}        101          30            .875[c](#cncr32465-note-0005){ref-type="fn"}
  A‐C                                             13 (7.1)                                         2 (5.6)                                                                            0 (0.0)      0 (0.0)        
  D                                               55 (30.1)                                        7 (19.4)                                                                           4 (4.0)      1 (3.3)        
  E                                               115 (62.8)                                       27 (75.0)                                                                          97 (96.0)    29 (96.7)      
  Bilsky Epidural Spinal Cord Compression Scale   177                                              35                             .389[b](#cncr32465-note-0004){ref-type="fn"}        91           29            .335[d](#cncr32465-note-0006){ref-type="fn"}
  0‐1C                                            95 (53.7)                                        16 (45.7)                                                                          86 (94.5)    29 (100.0)     
  2‐3                                             82 (46.3)                                        19 (54.3)                                                                          5 (5.5)      0 (0.0)        
  Education degree achieved, No. (%)              108                                              21                             **.012** [c](#cncr32465-note-0005){ref-type="fn"}   93           29            .827[c](#cncr32465-note-0005){ref-type="fn"}
  Primary/middle/high school                      28 (26)                                          12 (57.2)                                                                          29 (31.2)    9 (31.0)       
  Technical or trade degree                       20 (18.5)                                        3 (14.3)                                                                           11 (11.8)    4 (13.8)       
  College degree                                  44 (40.7)                                        4 (19.0)                                                                           40 (43.0)    10 (34.5)      
  Graduate degree                                 16 (14.8)                                        2 (9.5)                                                                            13 (14.0)    6 (20.7)       
  Current marital status, No. (%)                 183                                              36                             .237[b](#cncr32465-note-0004){ref-type="fn"}        101          31            **.011** [d](#cncr32465-note-0006){ref-type="fn"}
  Single                                          28 (15.3)                                        7 (19.4)                                                                           10 (9.9)     10 (32.3)      
  Living with a partner                           133 (72.7)                                       28 (77.8)                                                                          82 (81.2)    20 (64.5)      
  Unknown                                         22 (12.0)                                        1 (2.8)                                                                            9 (8.9)      1 (3.2)        

Abbreviations: ASIA, American Spinal Injury Association; ECOG, Eastern Cooperative Oncology Group.

Wilcoxon rank sum test.

Chi‐square test.

Cochran‐Armitage test for trend.

Fisher exact test.
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Satisfaction With Treatment Outcomes {#cncr32465-sec-0011}
------------------------------------

At 12 weeks after surgery, 183 patients (84%) were satisfied, 25 (11%) were neither satisfied nor dissatisfied, and 11 (5%) were dissatisfied with the results of their spine tumor management. Dissatisfaction after surgery was associated with a lower level of education (*P* = .012), discharge to home without family or home care support (*P* = .029), the occurrence of an intraoperative adverse event (*P* = .012), and a trend toward a worse baseline performance status (*P* = .056). The occurrence of a postoperative adverse event was not associated with dissatisfaction (*P* = .949). A significant difference in the 1‐year overall survival rate was found between satisfied and dissatisfied patients (*P* = .0285), with satisfied patients surviving longer than dissatisfied patients. No significant difference in the 3‐month overall survival rate was observed between satisfied and dissatisfied patients.

Of the patients treated with radiotherapy alone, 101 (77%) were satisfied, 24 (18%) were neither satisfied nor dissatisfied, and 7 (5%) were dissatisfied at 12 weeks after radiotherapy. Patients who were dissatisfied after radiotherapy were more likely to be living alone than patients who were satisfied after surgery (*P* = .011). The occurrence of an adverse event after radiotherapy was not associated with dissatisfaction (*P* = .340). The sensitivity analysis confirmed the results from the primary analyses. There was no statistical difference in satisfaction rates between the cohort undergoing surgery with or without radiotherapy and the cohort undergoing radiotherapy alone at 12 weeks after treatment. No significant difference in 1‐year overall survival between satisfied and dissatisfied patients was observed.

HRQOL and Treatment Satisfaction {#cncr32465-sec-0012}
--------------------------------

At baseline, patients who were dissatisfied after surgery were more likely to present with more severe leg weakness (*P* = .012) and a trend toward lower social functioning scores (*P* = .074) in comparison with patients who were satisfied. Baseline HRQOL scores of satisfied and dissatisfied patients did not demonstrate statistically significant differences in pain, physical function, mental health, or overall quality of life. At 12 weeks post‐surgery, a mean adjusted increase of 17.7 points (95%CI 12.0--23.5; *P*\<.001) in overall SOSGOQ2.0 score was observed for satisfied patients compared to an increase of 0.9 points (95%CI ‐13.8 ± 15.7; *P*=1.000) in patients who were dissatisfied. During follow‐up, satisfied patients experienced greater and significant improvements in almost all HRQOL domains and overall HRQOL in comparison with nonsignificant improvements in dissatisfied patients (Table [2](#cncr32465-tbl-0002){ref-type="table"}). More specifically, patients who were dissatisfied after surgery demonstrated worse mental health, social function, physical function, and pain scores at 12 weeks after surgery.

###### 

Mixed Effect Models for Patients Treated With Surgery With or Without Radiotherapy

                        Satisfied   Dissatisfied          *P* for Satisfied vs Dissatisfied[b](#cncr32465-note-0009){ref-type="fn"}                                                                            
  --------------------- ----------- --------------------- --------------------------------------------------------------------------- ------------ ---- --------------------- ------------------------ ------- ------------
  SOSGOQ2.0: overall                                                                                                                                                                                            
  Baseline              172         51.6 (49.8 to 53.3)                                                                                            32   50.9 (46.8 to 54.9)                                    1.000
  6 wk                  142         63.4 (60.5 to 66.4)   11.9 (6.7 to 17.0)                                                          **\<.001**   30   51.7 (45.1 to 58.2)   0.8 (--10.8 to 12.4)     1.000   **.046**
  12 wk                 127         69.2 (66.4 to 72.0)   17.6 (12.4 to 22.8)                                                         **\<.001**   19   50.8 (43.7 to 57.8)   --0.1 (--13.0 to 12.9)   1.000   **\<.001**
  26 wk                 102         71.3 (68.5 to 74.2)   19.8 (14.6 to 24.9)                                                         **\<.001**   11   54.2 (46.5 to 62.0)   3.4 (--10.5 to 17.3)     .999    **.003**
  SOSGOQ2.0: pain                                                                                                                                                                                               
  Baseline              172         36.2 (33.5 to 38.8)                                                                                            32   37.7 (31.5 to 43.8)                                    1.000
  6 wk                  143         58.0 (54.7 to 61.4)   21.8 (15.3 to 28.3)                                                         **\<.001**   31   44.0 (36.6 to 51.4)   6.3 (--8.3 to 20.9)      .926    **.028**
  12 wk                 128         65.1 (61.7 to 68.5)   28.9 (22.3 to 35.5)                                                         **\<.001**   19   42.9 (34.4 to 51.5)   5.3 (--10.9 to 21.4)     .988    **\<.001**
  26 wk                 103         65.1 (61.3 to 68.9)   28.9 (21.7 to 36.2)                                                         **\<.001**   12   44.1 (33.2 to 54.9)   6.4 (--13.2 to 26.0)     .988    **.015**
  SOSGOQ2.0: physical                                                                                                                                                                                           
  Baseline              173         50.0 (46.3 to 53.7)                                                                                            33   47.6 (39.0 to 56.2)                                    1.000
  6 wk                  144         54.6 (51.1 to 58.1)   4.6 (--2.3 to 11.5)                                                         .502         31   41.1 (33.4 to 48.8)   --6.5 (--21.9 to 8.9)    .936    **.058**
  12 wk                 130         63.8 (60.3 to 67.2)   13.7 (7.1 to 20.3)                                                          **\<.001**   19   44.4 (35.7 to 53.1)   --3.2 (--19.4 to 13.0)   1.000   **.003**
  26 wk                 102         68.1 (64.5 to 71.7)   18.1 (11.3 to 24.9)                                                         **\<.001**   12   53.7 (44.4 to 63.1)   6.1 (--11.0 to 23.3)     .978    .138
  SOSGOQ2.0: mental                                                                                                                                                                                             
  Baseline              173         61.3 (57.8 to 64.8)                                                                                            33   58.4 (50.3 to 66.5)                                    1.000
  6 wk                  145         70.2 (66.3 to 74.1)   8.9 (2.5 to 15.3)                                                           **\<.001**   31   58.5 (49.9 to 67.1)   0.1 (--14.0 to 14.1)     1.000   .311
  12 wk                 129         73.3 (69.5 to 77.1)   12.0 (5.2 to 18.8)                                                          **\<.001**   19   55.0 (45.3 to 64.6)   --3.4 (--20.4 to 13.5)   1.000   **.022**
  26 wk                 103         74.6 (70.8 to 78.5)   13.3 (6.3 to 20.4)                                                          **\<.001**   12   59.2 (48.4 to 70.0)   0.8 (--18.2 to 19.9)     1.000   .202
  SOSGOQ2.0: social                                                                                                                                                                                             
  Baseline              173         56.5 (52.3 to 60.7)                                                                                            33   49.5 (40.8 to 58.3)                                    .894
  6 wk                  150         68.1 (64.3 to 71.9)   11.6 (5.2 to 18.1)                                                          **\<.001**   31   54.9 (47.3 to 62.5)   5.4 (--9.1 to 19.9)      .973    **.038**
  12 wk                 134         72.6 (68.9 to 76.4)   16.2 (9.8 to 22.5)                                                          **\<.001**   22   54.7 (46.8 to 62.7)   5.2 (--10.2 to 20.6)     .986    **.001**
  26 wk                 108         74.0 (70.1 to 77.9)   17.6 (10.8 to 24.4)                                                         **\<.001**   13   53.5 (44.1 to 62.9)   4.0 (--13.7 to 21.7)     .999    **.002**
  EQ‐5D (3L)                                                                                                                                                                                                    
  Baseline              169         0.49 (0.45 to 0.53)                                                                                            33   0.44 (0.34 to 0.53)                                    .994
  6 wk                  144         0.66 (0.62 to 0.69)   0.17 (0.10 to 0.24)                                                         **\<.001**   32   0.50 (0.42 to 0.57)   0.06 (--0.09 to 0.21)    .962    **.006**
  12 wk                 129         0.74 (0.71 to 0.76)   0.25 (0.18 to 0.32)                                                         **\<.001**   19   0.57 (0.50 to 0.65)   0.14 (--0.03 to 0.31)    .221    **.003**
  26 wk                 103         0.70 (0.66 to 0.73)   0.21 (0.13 to 0.29)                                                         **\<.001**   12   0.62 (0.52 to 0.71)   0.18 (--0.02 to 0.38)    .139    .877

Abbreviations: 3L, 3‐level version; EQ‐5D, EuroQol 5‐Dimension; SOSGOQ2.0, Spine Oncology Study Group Outcomes Questionnaire.

Adjusted *P* values Tukey‐Kramer for comparisons of changes with the baseline value per group.

*P* values for comparisons of the mean values of both groups.

John Wiley & Sons, Ltd

Among patients treated with radiotherapy alone, no differences in baseline HRQOL scores were observed between satisfied and dissatisfied patients except for a trend toward lower social functioning scores (*P* = .070) and more severe arm weakness (*P* = .080). Patients who were satisfied after radiotherapy were demonstrated to have significant improvements in pain at 12 weeks after radiotherapy (12.3; 95% CI, 4.1‐20.6; *P* \< .001) in contrast to deterioration of pain scores for patients who were dissatisfied (--9.9; 95% CI, --24.7 to 4.9; *P* = .483). Patients who were satisfied after radiotherapy maintained their baseline HRQOL or experienced moderate improvements in HRQOL in contrast to deterioration of HRQOL in patients who were dissatisfied (Table [3](#cncr32465-tbl-0003){ref-type="table"}).

###### 

Mixed Effect Models for Patients Treated With Radiotherapy Alone

                        Satisfied   Not Satisfied         *P* for Satisfied vs Dissatisfied[b](#cncr32465-note-0109){ref-type="fn"}                                                                                 
  --------------------- ----------- --------------------- --------------------------------------------------------------------------- ------------ ---- --------------------- -------------------------- ---------- ------------
  SOSGOQ2.0: overall                                                                                                                                                                                                 
  Baseline              98          68.0 (66.1 to 69.8)                                                                                            31   68.4 (65.1 to 71.8)                                         1.000
  6 wk                  89          71.0 (68.6 to 73.3)   3.0 (--1.0 to 6.9)                                                          .327         25   68.4 (64.1 to 72.8)   --0.0 (--7.3 to 7.3)       1.000      .992
  12 wk                 79          73.5 (70.8 to 76.1)   5.5 (0.8 to 10.1)                                                           **.009**     25   61.2 (56.4 to 66.0)   --7.2 (--15.5 to 1.1)      .146       **.001**
  26 wk                 69          71.9 (68.6 to 75.2)   3.9 (--1.6 to 9.4)                                                          .402         18   66.9 (60.6 to 73.2)   --1.5 (--12.1 to 9.0)      1.000      .927
  SOSGOQ2.0: pain                                                                                                                                                                                                    
  Baseline              99          59.4 (55.6 to 63.3)                                                                                            31   61.5 (54.6 to 68.4)                                         1.000
  6 wk                  89          67.5 (63.9 to 71.1)   8.1 (1.1 to 15.1)                                                           **.011**     25   61.9 (55.2 to 68.6)   0.4 (--12.5 to 13.2)       1.000      .902
  12 wk                 79          71.7 (67.8 to 75.6)   12.3 (4.1 to 20.6)                                                          **\<.001**   25   51.6 (44.6 to 58.7)   --9.9 (--24.7 to 4.9)      .483       **\<.001**
  26 wk                 69          67.6 (63.2 to 72.0)   8.2 (--0.1 to 16.5)                                                         .053         18   59.1 (50.5 to 67.6)   --2.4 (--18.1 to 13.3)     1.000      .754
  SOSGOQ2.0: physical                                                                                                                                                                                                
  Baseline              99          75.5 (72.3 to 78.8)                                                                                            31   75.3 (69.4 to 81.2)                                         1.000
  6 wk                  89          73.3 (69.7 to 76.8)   --2.3 (--6.8 to 2.3)                                                        .838         26   74.4 (67.9 to 80.8)   --0.9 (--9.1 to 7.3)       1.000      1.000
  12 wk                 83          75.5 (72.1 to 78.9)   --0.0 (--5.5 to 5.5)                                                        1.000        25   65.2 (59.1 to 71.4)   --10.1 (--20.0 to --0.1)   **.044**   .123
  26 wk                 70          70.3 (65.8 to 74.8)   --5.2 (--12.4 to 2.0)                                                       .362         18   67.7 (58.9 to 76.5)   --7.6 (--21.7 to 6.4)      .756       1.000
  SOSGOQ2.0: mental                                                                                                                                                                                                  
  Baseline              99          60.3 (55.6 to 65.0)                                                                                            31   60.1 (51.6 to 68.5)                                         1.000
  6 wk                  89          65.9 (61.5 to 70.4)   5.6 (--0.4 to 11.7)                                                         .091         25   59.6 (51.3 to 68.0)   --0.4 (--11.7 to 10.8)     1.000      .947
  12 wk                 79          67.1 (62.8 to 71.4)   6.8 (0.6 to 12.9)                                                           **.018**     25   61.7 (53.9 to 69.4)   1.6 (--9.4 to 12.6)        1.000      .969
  26 wk                 69          68.1 (63.2 to 73.0)   7.8 (--0.7 to 16.2)                                                         .097         18   66.2 (56.7 to 75.6)   6.1 (--10.0 to 22.2)       .967       1.000
  SOSGOQ2.0: social                                                                                                                                                                                                  
  Baseline              100         75.8 (70.3 to 81.3)                                                                                            31   69.7 (61.4 to 78.0)                                         .937
  6 wk                  90          76.4 (70.9 to 81.8)   0.6 (--5.3 to 6.5)                                                          1.000        26   71.5 (63.2 to 79.7)   1.7 (--9.1 to 12.5)        1.000      .983
  12 wk                 83          78.4 (73.1 to 83.7)   2.6 (--3.5 to 8.7)                                                          .925         25   59.5 (51.5 to 67.4)   --10.2 (--21.2 to 0.8)     .091       **\<.001**
  26 wk                 71          79.7 (74.3 to 85.2)   3.9 (--2.3 to 10.2)                                                         .567         18   67.8 (59.4 to 76.3)   --1.9 (--13.9 to 10.1)     1.000      .219
  EQ‐5D (3L)                                                                                                                                                                                                         
  Baseline              94          0.72 (0.68 to 0.76)                                                                                            31   0.70 (0.63 to 0.77)                                         1.000
  6 wk                  88          0.78 (0.75 to 0.80)   0.05 (--0.01 to 0.12)                                                       .191         26   0.72 (0.67 to 0.77)   0.02 (--0.09 to 0.13)      1.000      .724
  12 wk                 83          0.76 (0.73 to 0.80)   0.04 (--0.03 to 0.11)                                                       .693         24   0.67 (0.61 to 0.74)   --0.03 (--0.15 to 0.10)    1.000      .343
  26 wk                 69          0.74 (0.70 to 0.78)   0.02 (--0.06 to 0.10)                                                       .997         18   0.72 (0.64 to 0.79)   0.02 (--0.14 to 0.17)      1.000      1.000

Abbreviations: 3L, 3‐level version; EQ‐5D, EuroQol 5‐Dimension; SOSGOQ2.0, Spine Oncology Study Group Outcomes Questionnaire. a= Adjusted P value by Tukey‐Kramer for comparison of change to baseline value per group.

Adjusted *P* values Tukey‐Kramer for comparisons of changes with the baseline value per group.

*P* values for comparisons of the mean values of both groups.

John Wiley & Sons, Ltd

Satisfaction Over Time {#cncr32465-sec-0013}
----------------------

During 6 months of follow‐up, 75% of the surgically treated patients reported only satisfaction with treatment outcomes, 12% reported only dissatisfaction, and 13% reported both satisfaction and dissatisfaction. In comparison, of the patients treated with radiotherapy alone, 64% reported only satisfaction with treatment outcomes, 10% reported only dissatisfaction, and 26% reported both satisfaction and dissatisfaction.

Discussion {#cncr32465-sec-0014}
==========

The patient perspective is essential to evaluating surgery and/or radiotherapy for the treatment of spinal metastases, especially when the treatment objectives are symptom relief and improvement in HRQOL. At 12 weeks after treatment, we demonstrated that among the patients who underwent surgery with or without radiotherapy and the patients who underwent radiotherapy alone for the treatment of spinal metastases, 84% and 77%, respectively, were satisfied with their treatment results. Only 5% of the patients reported dissatisfaction at 12 weeks after treatment. Previously, Fujibayashi et al[7](#cncr32465-bib-0007){ref-type="ref"} reported a similar satisfaction rate of 81% based on an evaluation of 21 patients and 16 family members after surgical treatment for spinal metastases. Moreover, Kato et al[8](#cncr32465-bib-0008){ref-type="ref"} reported a satisfaction rate of 95% after en bloc spondylectomy with curative intent for spinal metastases in 47 patients and 67 family members. However, both studies used a cross‐sectional study design with overall questionnaire response rates of 52% and 58%, respectively, and they performed the evaluation at an average of 32.7 and 58 months after surgery, respectively. In comparison, our overall questionnaire response rates were 69% at 6 weeks and 61% at 12 weeks. When we excluded patients who died during follow‐up, our response rates were 76% at 6 weeks and 74% at 12 weeks. These questionnaire completions rates are remarkable given the complexity around the follow‐up of oncology patients.

Interestingly, the satisfaction rates found in our study after surgical treatment are markedly higher than the reported satisfaction rates after surgery for adult spinal deformity and lumbar spinal stenosis of 75.8% and 62.4%, respectively.[10](#cncr32465-bib-0010){ref-type="ref"}, [11](#cncr32465-bib-0011){ref-type="ref"} In agreement with our results, both studies showed an association between significant improvements in HRQOL and satisfaction with treatment outcomes.[10](#cncr32465-bib-0010){ref-type="ref"}, [11](#cncr32465-bib-0011){ref-type="ref"} In addition, Hamilton et al[10](#cncr32465-bib-0010){ref-type="ref"} also showed no relation between the occurrence of adverse events (major or minor) and satisfaction. The high rates of satisfaction in both cohorts are in line with results after other palliative cancer treatments despite high morbidity rates and poor overall survival.[12](#cncr32465-bib-0012){ref-type="ref"} Surgery for spinal metastases is, despite the advances in surgical techniques, often invasive surgery as reflected by reported adverse event rates of up to 76%.[13](#cncr32465-bib-0013){ref-type="ref"} The reported incidence of adverse events with radiotherapy is similar, yet the adverse event profile is substantially less severe in comparison with surgical adverse events.[14](#cncr32465-bib-0014){ref-type="ref"} In the current study, posttreatment adverse events were reported in 33% of the surgically treated patients and in 12% of the radiotherapy patients. The occurrence of an adverse event, with the exception of the occurrence of an intraoperative adverse event, was in neither of the groups associated with dissatisfaction after treatment. This may be explained by the severity of an intraoperative adverse event in comparison with the severity of the majority of postoperative adverse events. Despite the high risk of adverse events and the poor prospects of overall survival, the benefit of the procedures to the patients should not be underestimated, as is emphasized by the satisfaction rates and improvements in HRQOL demonstrated in this study.

Our study demonstrated that patients who were satisfied after surgery experienced significant improvements in HRQOL in contrast to nonsignificant improvements in HRQOL in dissatisfied patients. On the other hand, patients who were satisfied after radiotherapy experienced significant improvements in pain but not in other HRQOL domains. Despite this difference in HRQOL outcomes between surgery and radiotherapy, satisfaction rates between the 2 treatment groups were not significantly different. This may be explained by how satisfaction with treatment outcomes was previously defined as the valuation of the results of a treatment in comparison with pretreatment expectations and in light of patients\' preferences.[15](#cncr32465-bib-0015){ref-type="ref"} Counseling patients toward appropriate expectations may, therefore, be crucial in further optimizing HRQOL and satisfaction with treatment outcomes[16](#cncr32465-bib-0016){ref-type="ref"} and may explain the similarity of satisfaction rates after surgery and radiotherapy despite the difference in HRQOL outcomes. Pretreatment expectations were, however, not evaluated in the current study.

Dissatisfaction after radiotherapy and/or surgery was associated with lower baseline social functioning scores, being single, and being discharged home without family or home care support. In addition, lower mental health and social functioning were observed at 12 weeks after treatment in dissatisfied patients. The amount of social support is a factor known to be associated with HRQOL outcomes.[17](#cncr32465-bib-0017){ref-type="ref"} Social life and the ability to participate in social life may help or hamper the recovery process of a treatment and influence HRQOL and posttreatment satisfaction.[17](#cncr32465-bib-0017){ref-type="ref"} Close involvement of patient support services and posthospital care, in addition to treatment‐related care, may help to further improve HRQOL outcomes. Besides social functioning, more severe pretreatment neurological deficits of the arms or legs were also associated with dissatisfaction after surgery and/or radiotherapy. Neurological deficits have a debilitating effect on HRQOL and functional status; therefore, these patients may have had higher expectations of the functional outcomes and could be harder to satisfy.[18](#cncr32465-bib-0018){ref-type="ref"}

Though promising, the high satisfaction rates after surgery and radiotherapy reported in this study merit further consideration. Satisfaction was measured with a 5‐point response scale, with the majority of satisfied people reporting that they were very satisfied with the results of their spine tumor management. A ceiling effect of the satisfaction scale should be considered because the high satisfaction rates may not necessarily reflect only positive outcomes.[18](#cncr32465-bib-0018){ref-type="ref"} Furthermore, the number of dissatisfied and neither satisfied nor dissatisfied patients may reflect a lower level of dissatisfaction because patients may express dissatisfaction only after a profoundly negative experience.[15](#cncr32465-bib-0015){ref-type="ref"}, [18](#cncr32465-bib-0018){ref-type="ref"} In addition, the low number of dissatisfied patients also limited the ability to detect statistically significant changes in HRQOL among these patients. Although our response rates can be considered high in light of the study population, approximately 25% did not complete the satisfaction questions. Moreover, 12 of our patients died, and 7 were lost to follow‐up or withdrew consent within the first 12 weeks after treatment. Satisfaction with treatment outcomes for these patients might have been different from that for the patients who completed the HRQOL questionnaires, and this potentially could have resulted in an overestimation of satisfaction. The LOCF approach was used to minimize this.

In conclusion, high rates of patient satisfaction with outcomes of surgery with or without radiotherapy or radiotherapy alone for spinal metastases were reported. No differences in satisfaction rates were found between the 2 treatment groups despite a greater effect of surgery with or without radiotherapy in comparison with radiotherapy alone on HRQOL. Dissatisfaction after radiotherapy and/or surgery was associated with no improvement in or a deterioration of HRQOL, being single, and being discharged home without family or homecare support. Dissatisfied patients reported worse mental health, social function, physical function, and pain scores at 12 weeks after treatment. Future studies evaluating patient satisfaction should try to identify prognostic factors associated with dissatisfaction or satisfaction with treatment outcomes. Ideally, these risk factors can be addressed before treatment or shortly after treatment (eg, enhanced patient support services) to improve satisfaction rates and overall HRQOL.
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